TKNO Stock Overview
Produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Alpha Teknova, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.36 |
| 52 Week High | US$5.46 |
| 52 Week Low | US$1.16 |
| Beta | 0.44 |
| 11 Month Change | -13.66% |
| 3 Month Change | 213.67% |
| 1 Year Change | 41.10% |
| 33 Year Change | -82.33% |
| 5 Year Change | n/a |
| Change since IPO | -82.56% |
Recent News & Updates
Recent updates
Alpha Teknova, Inc. (NASDAQ:TKNO) Might Not Be As Mispriced As It Looks After Plunging 30%
Jun 27
Not Many Are Piling Into Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Yet As It Plummets 25%
Apr 24Health Check: How Prudently Does Alpha Teknova (NASDAQ:TKNO) Use Debt?
Jan 22Some Analysts Just Cut Their Alpha Teknova, Inc. (NASDAQ:TKNO) Estimates
Aug 14Take Care Before Jumping Onto Alpha Teknova, Inc. (NASDAQ:TKNO) Even Though It's 30% Cheaper
Apr 17Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported, And Analysts Assigned A US$23.00 Price Target
May 14Shareholder Returns
| TKNO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -13.0% | -2.3% | 1.8% |
| 1Y | 41.1% | 10.0% | 31.9% |
Return vs Industry: TKNO exceeded the US Life Sciences industry which returned 13.1% over the past year.
Return vs Market: TKNO exceeded the US Market which returned 32.8% over the past year.
Price Volatility
| TKNO volatility | |
|---|---|
| TKNO Average Weekly Movement | 19.7% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TKNO's share price has been volatile over the past 3 months.
Volatility Over Time: TKNO's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 211 | Stephen Gunstream | www.teknova.com |
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
Alpha Teknova, Inc. Fundamentals Summary
| TKNO fundamental statistics | |
|---|---|
| Market cap | US$251.06m |
| Earnings (TTM) | -US$34.27m |
| Revenue (TTM) | US$34.94m |
6.7x
P/S Ratio-6.8x
P/E RatioIs TKNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TKNO income statement (TTM) | |
|---|---|
| Revenue | US$34.94m |
| Cost of Revenue | US$27.12m |
| Gross Profit | US$7.82m |
| Other Expenses | US$42.09m |
| Earnings | -US$34.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 22.38% |
| Net Profit Margin | -98.08% |
| Debt/Equity Ratio | 16.8% |
How did TKNO perform over the long term?
See historical performance and comparison